FDA Warning Letter to Bausch & Lomb Inc. (2026-09-04) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
In short: On September 4, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Bausch & Lomb Inc. (FEI 1000113778) in Tampa, Florida, following an inspection conducted March 12-20, 2026, documenting significant Current Good Manufacturing Practice (CGMP) violations in finished pharmaceutical manufacturing under 21 CFR parts 210 and 211. The letter cites inadequate environmental and personnel monitoring in aseptic ISO 5 processing areas, routine out-of-limit microorganism recoveries (including water-source organisms like Serratia marcescens and Stenotrophomonas maltophilia) from 2023-2025 without sufficient corrective action, design deficiencies in the restricted access barrier system line including insufficient unidirectional airflow demonstration, and failure to implement adequate design remediations—rendering the drug products adulterated under FD&C Act section 501(a)(2)(B).
Argus analysis
# FDA Warning Letter Analysis: Bausch & Lomb Inc.
**Company and Findings**
Bausch & Lomb Inc., a sterile drug manufacturer operating at 8500 Hidden River Parkway in Tampa, Florida, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on September 4, 2026, following an inspection conducted March 12–20, 2026. The FDA identified significant Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter sterile drug products. The agency determined that the facility's methods, facilities, and controls do not conform to CGMP requirements, rendering finished drug products adulterated under federal law.
**Regulatory Citations and Their Significance**
The warning letter cites 21 CFR 211.42(c)(10) regarding inadequate separation and control of aseptic processing areas, and 21 CFR 211.113(b) concerning failure to establish written procedures preventing microbiological contamination in sterile drug production. These sections form the backbone of sterile manufacturing requirements. The FDA documented persistent recovery of gram-negative organisms (Serratia marcescens, Stenotrophomonas maltophilia, Pseudomonas aeruginosa) and fungi (Aspergillus brasiliensis) from ISO 5 critical areas from 2023 through 2025—organisms commonly associated with water contamination. Environmental monitoring procedures were insufficient, including inadequate culture media and incomplete facility coverage. The agency noted the same microorganism genera and species recovered from consumer complaints, indicating potential product safety implications.
**Response Timeline and Industry Watch Points**
Bausch & Lomb submitted an April 10, 2026 Form FDA 483 response, which the FDA found inadequate. The company must now provide independent assessments of environmental monitoring programs, manufacturing design reviews, batch investigations, microbiological specifications, and validated smoke studies demonstrating proper aseptic airflow. Compliance officers monitoring this facility should watch for product recalls, customer notifications regarding potentially contaminated batches, and facility remediation timelines. The agency explicitly stated that sterility testing alone cannot justify batch release, signaling heightened scrutiny of Bausch & Lomb's quality controls going forward.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Bausch & Lomb Inc. MARCS-CMS 732398 — September 04, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: 320-26-123 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Robert T. Fulop Recipient Title Director of Site Operations Bausch & Lomb Inc. 8500 Hidden River Parkway Tampa , FL 33637-1014 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 4, 2026 WARNING LETTER Reference number: 320-26-123 To Mr. Robert T. Fulop: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Bausch & Lomb Inc., FDA Establishment Identifier (FEI) 1000113778, at 8500 Hidden River Parkway, Tampa, from March 12 to 20, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your April 10, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)). Inadequate Monitoring of Aseptic Processing Your firm is a manufacturer of sterile prescription and over-the-counter (OTC) (b)(4) drug products produced by aseptic proce…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Bausch & Lomb Inc.?
- FDA issued the letter (MARCS-CMS 732398) on 2026-09-04 and posted it publicly on fda.gov on 2026-09-15.
- Is the FDA warning letter to Bausch & Lomb Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Bausch & Lomb Inc. (2026-09-04) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-bausch-and-lomb-inc-2026-09-04-cgmp
"FDA Warning Letter to Bausch & Lomb Inc. (2026-09-04) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-bausch-and-lomb-inc-2026-09-04-cgmp.
Argus HQ Research. "FDA Warning Letter to Bausch & Lomb Inc. (2026-09-04) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 16, 2026. https://argushq.ai/fda/warning-letter/fda-wl-bausch-and-lomb-inc-2026-09-04-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_bausch_and_lomb_inc_2026_09_04_cgmp_2026,
title = {FDA Warning Letter to Bausch & Lomb Inc. (2026-09-04) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-bausch-and-lomb-inc-2026-09-04-cgmp},
note = {Accessed: September 16, 2026}
}